Form 8-K

8-K — Amneal Pharmaceuticals, Inc.

Accession: 0001723128-26-000025

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0001723128

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — amrx-20260730.htm (Primary)

EX-99.1 (amrx-q22026ex991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: amrx-20260730.htm · Sequence: 1

amrx-20260730

false000172312800017231282026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 30, 2026

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-38485 93-4225266

(State or other jurisdiction

of incorporation) (Commission File Number) (IRS Employer

Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 7.01

Regulation FD Disclosure

Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, July 30, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 901153095. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers.

The information in this report furnished pursuant to Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit No. Description

99.1

Press release issued July 30, 2026.

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 30, 2026

AMNEAL PHARMACEUTICALS, INC.

By: /s/ Anastasios Konidaris

Name: Anastasios Konidaris

Title: Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-99.1

Filename: amrx-q22026ex991.htm · Sequence: 2

Document

Exhibit 99.1

AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 –

– Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 –

– Raising 2026 Full Year Guidance –

– Successful Debt Repricing in July Reduces Interest Cost –

BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026.

“Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

Second Quarter 2026 Results

Net revenue in the second quarter of 2026 was $796 million, an increase of 10% compared to $725 million in the second quarter of 2025. Specialty net revenue increased 17%, driven by key branded products, including CREXONT®, BREKIYA® autoinjector, and UNITHROID®. Affordable Medicines net revenue increased 13%, driven by strong performance of our complex portfolio, including women’s health products, and new product launches. AvKARE net revenue decreased 4% due to a decline in the low margin distribution channel partially offset by growth in the government channel.

Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in the second quarter of 2026 compared to net income of $22 million in the second quarter of 2025, an increase of 157%, as higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense.

Adjusted EBITDA in the second quarter of 2026 was $206 million, an increase of 12% compared to the second quarter of 2025, reflecting higher revenue and gross profit.

Diluted income per share in the second quarter of 2026 was $0.18 compared to diluted income per share of $0.07 for the second quarter of 2025, an increase of 157%, due to the aforementioned factors. Adjusted diluted earnings per share in the second quarter of 2026 was $0.30, an increase of 20% compared to $0.25 for the second quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

Debt Repricing Further Reduces Future Interest Cost

In July 2026, the Company launched a repricing of its $2.084B Term Loan B, which will reduce the interest rate by 50 basis points from Secured Overnight Financing Rate (“SOFR”) plus 300 basis points to SOFR plus 250 basis points. The repricing is expected to close as early as August 3, 2026.

The Company also intends to obtain an additional $350 million Term Loan B financing to fund a portion of the purchase price of Kashiv Biosciences, as previously disclosed. Such additional Term Loans are expected to be incurred at the closing of the Kashiv acquisition at the reduced pricing. The repricing transaction is expected to generate about $12 million in annual cash interest savings and contribute towards the Company’s goal to reduce net leverage to below 3.0x by 2028.

Raising 2026 Full Year Guidance

We are raising select full year 2026 guidance metrics.

Updated Guidance

Prior Guidance

Net revenue

$3.10 billion - $3.20 billion

$3.05 billion - $3.15 billion

Adjusted EBITDA (1)

$750 million - $780 million

$740 million - $770 million

Adjusted diluted EPS (2)

$0.96 - $1.06

$0.95 - $1.05

Operating cash flow (3)

$350 million - $400 million

Operating cash flow, excluding discrete items (4)

$375 million - $425 million

Capital expenditures (5)

~$150 million

~$110 million

(1)Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.

(2)Accounts for 35% non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.

(3)Represents cash provided by operating activities.

(4)Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $30 million.

(5)Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other

events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to our proposed transaction to acquire membership interests of Kashiv BioSciences, LLC (“Kashiv”), our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working

capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Net revenue $ 796,197 $ 724,508 $ 1,518,716 $ 1,419,928

Cost of goods sold 461,689 438,255 864,095 877,784

Gross profit 334,508 286,253 654,621 542,144

Selling, general and administrative 148,722 124,266 287,582 242,554

Research and development 39,017 47,964 77,400 88,004

Intellectual property legal development expenses 2,087 2,017 3,629 3,784

Acquisition costs 7,600 — 12,753 —

Restructuring and other charges 554 1,024 1,204 1,595

Charges (credit) related to legal matters, net 8,057 (390) 8,751 (390)

Other operating income (1,298) — (8,239) (5,122)

Operating income 129,769 111,372 271,541 211,719

Other (expense) income:

Interest expense, net (55,043) (65,101) (108,404) (122,040)

Foreign exchange (loss) gain, net (1,950) 8,256 (9,750) 12,503

Loss on refinancing — — (3,510) —

Increase in tax receivable agreement liability (2,439) (4,420) (106) (15,107)

Other income, net 653 1,604 1,395 2,122

Total other expense, net (58,779) (59,661) (120,375) (122,522)

Income before income taxes 70,990 51,711 151,166 89,197

Provision for income taxes 1,376 16,101 3,552 28,969

Net income 69,614 35,610 147,614 60,228

Less: Net income attributable to non-controlling interests (11,952) (13,193) (27,696) (25,616)

Net income attributable to Amneal Pharmaceuticals, Inc. $ 57,662 $ 22,417 $ 119,918 $ 34,612

Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:

Basic $ 0.18 $ 0.07 $ 0.38 $ 0.11

Diluted $ 0.18 $ 0.07 $ 0.37 $ 0.11

Weighted-average common shares outstanding:

Basic 319,200 313,739 317,620 312,404

Diluted 328,102 322,363 328,527 323,171

Amneal Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands)

June 30, 2026 December 31, 2025

Assets

Current assets:

Cash and cash equivalents $ 127,637 $ 282,029

Restricted cash 8,643 28,842

Trade accounts receivable, net 1,020,360 895,143

Inventories 677,954 606,302

Prepaid expenses and other current assets 112,011 98,395

Related party receivables 424 470

Total current assets 1,947,029 1,911,181

Property, plant and equipment, net 456,877 442,950

Goodwill 593,499 595,470

Intangible assets, net 587,830 563,498

Operating lease right-of-use assets 44,361 38,832

Operating lease right-of-use assets - related party 13,723 15,216

Financing lease right-of-use assets 52,360 53,328

Other assets 80,669 57,805

Total assets $ 3,776,348 $ 3,678,280

Liabilities and Stockholders’ Equity (Deficiency)

Current liabilities:

Accounts payable and accrued expenses $ 721,208 $ 761,316

Current portion of liabilities for legal matters 18,488 43,256

Revolving credit facility 100,000 —

Current portion of long-term debt, net 5,961 6,761

Current portion of operating lease liabilities 9,040 8,668

Current portion of operating lease liabilities - related party 2,899 2,705

Current portion of financing lease liabilities 3,521 3,442

Related party payables - short term 22,070 55,485

Total current liabilities 883,187 881,633

Long-term debt, net 2,564,335 2,565,115

Operating lease liabilities 38,691 33,233

Operating lease liabilities - related party 12,712 14,195

Financing lease liabilities 54,602 54,927

Related party payables - long term 2,892 19,132

Liabilities for legal matters - long term 70,830 71,819

Other long-term liabilities 32,119 32,263

Total long-term liabilities 2,776,181 2,790,684

Redeemable non-controlling interests 83,956 77,292

Total stockholders’ equity (deficiency)

33,024 (71,329)

Total liabilities and stockholders’ equity (deficiency)

$ 3,776,348 $ 3,678,280

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(unaudited; in thousands)

Six Months Ended June 30,

2026 2025

Cash flows from operating activities:

Net income $ 147,614 $ 60,228

Adjustments to reconcile net income to net cash (used in) provided by operating activities:

Depreciation and amortization 90,991 120,272

Unrealized foreign currency loss (gain) 10,495 (11,813)

Amortization of debt issuance costs and discount 7,954 13,686

Reclassification of cash flow hedge 5,788 (5,876)

Loss on refinancing 3,510 —

Stock-based compensation 19,208 15,532

Inventory provision 44,957 38,432

Other operating charges and credits, net 3,086 2,254

Changes in assets and liabilities:

Trade accounts receivable, net (125,765) (32,615)

Inventories (124,150) (36,039)

Prepaid expenses, other current assets and other assets (24,150) (10,015)

Related party receivables 25 (1,108)

Accounts payable, accrued expenses and other liabilities (57,918) (67,004)

Related party payables (49,632) 5,293

Net cash (used in) provided by operating activities (47,987) 91,227

Cash flows from investing activities:

Purchases of property, plant and equipment (38,872) (35,992)

Acquisition of intangible assets (85,000) (5,100)

Deposits for future acquisition of property, plant and equipment (20,580) (4,632)

Proceeds from sale of property, plant and equipment — 1,379

Net cash used in investing activities (144,452) (44,345)

Cash flows from financing activities:

Payments of principal on debt, revolving credit facilities, financing leases and other (147,027) (251,076)

Proceeds from issuance of debt 134,673 —

Payments of deferred financing and refinancing costs (1,982) (1,745)

Borrowings on revolving credit facilities 100,000 218,000

Proceeds from exercise of stock options 80 754

Employee payroll tax withholding on restricted stock unit and performance stock unit vesting (44,481) (21,828)

Tax and other distributions to non-controlling interests (21,067) (24,958)

Proceeds from alliance party 510 —

Acquisition of non-controlling interest (400) —

Net cash provided by (used in) financing activities 20,306 (80,853)

Effect of foreign exchange rate on cash (1,187) (777)

Net decrease in cash, cash equivalents, and restricted cash (173,320) (34,748)

Cash, cash equivalents, and restricted cash - beginning of period 312,939 118,420

Cash, cash equivalents, and restricted cash - end of period $ 139,619 $ 83,672

Cash and cash equivalents - end of period $ 127,637 $ 71,544

Restricted cash - end of period 8,643 9,642

Long-term restricted cash included in other assets - end of period 3,339 2,486

Cash, cash equivalents, and restricted cash - end of period $ 139,619 $ 83,672

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, in thousands)

Reconciliation of Net Income to EBITDA and Adjusted EBITDA

Three Months Ended June 30, Six Months Ended June 30, Year Ended

December 31,

2026 2025 2026 2025 2025

Net income $ 69,614 $ 35,610 $ 147,614 $ 60,228 $ 127,933

Adjusted to add:

Interest expense, net 55,043 65,101 108,404 122,040 241,091

Provision for income taxes 1,376 16,101 3,552 28,969 11,276

Depreciation and amortization 47,800 60,113 90,991 120,272 223,572

EBITDA (Non-GAAP) $ 173,833 $ 176,925 $ 350,561 $ 331,509 $ 603,872

Adjusted to add (deduct):

Stock-based compensation expense 10,392 8,274 19,208 15,402 31,823

Acquisition, site closure, and idle facility expenses (1)

8,076 1,203 13,758 2,444 5,301

Restructuring and other charges — 1,024 499 1,595 4,208

Loss on refinancing (2)

— — 3,510 — 31,365

Charges (credit) related to legal matters, net (3)

8,057 (390) 8,751 (390) (390)

Asset impairment charges (4)

— 36 — 104 23,022

Foreign exchange loss (gain) 1,950 (8,256) 9,750 (12,503) (7,635)

Increase in tax receivable agreement liability 2,439 4,420 106 15,107 6,588

Other (5)

1,703 424 2,317 370 (9,739)

Adjusted EBITDA (Non-GAAP) $ 206,450 $ 183,660 $ 408,460 $ 353,638 $ 688,415

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Calculation of Net Debt and Net Leverage

June 30, 2026 December 31, 2025

Term Loan Due 2032 $ 2,084,263 $ 2,094,750

Senior Notes Due 2032 600,000 600,000

2025 Revolving Credit Facility 100,000 —

Gross debt (6)

$ 2,784,263 $ 2,694,750

Less: Cash and cash equivalents 127,637 282,029

Net debt (Non-GAAP) (7)

$ 2,656,626 $ 2,412,721

Adjusted EBITDA (Non-GAAP) Adjusted EBITDA (Non-GAAP)

Year ended December 31, 2025 $ 688,415 $ 688,415

Less: Six months ended June 30, 2025 353,638

Add: Six months ended June 30, 2026 408,460

Last twelve months ended June 30, 2026 $ 743,237

Last Twelve Months Ended

June 30, 2026

Year Ended December 31, 2025

Gross leverage (Non-GAAP) (8)

3.7x 3.9x

Net leverage (Non-GAAP) (9)

3.6x 3.5x

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited; in thousands, except per share amounts)

Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

Net income $ 69,614 $ 35,610 $ 147,614 $ 60,228

Adjusted to add (deduct):

Non-cash interest 6,944 7,411 13,681 7,745

GAAP provision for income taxes 1,376 16,101 3,552 28,969

Amortization 34,004 44,820 63,025 89,094

Stock-based compensation expense 10,392 8,274 19,208 15,402

Acquisition, site closure, and idle facility expenses (1)

8,076 1,189 13,758 2,416

Restructuring and other charges — 1,017 499 1,588

Loss on refinancing — — 3,510 —

Charges (credit) related to legal matters, including interest, net (3)

9,117 (390) 10,567 (390)

Asset impairment charges — 36 — 104

Increase in tax receivable agreement liability 2,439 4,420 106 15,107

Other 1,703 424 2,317 380

Provision for income taxes (10)

(33,005) (26,089) (61,760) (48,854)

Net income attributable to non-controlling interests (11,952) (13,193) (27,696) (25,616)

Adjusted net income (Non-GAAP) $ 98,708 $ 79,630 $ 188,381 $ 146,173

Weighted average diluted shares outstanding (11)

328,102 322,363 328,527 323,171

Diluted earnings per share (GAAP) $ 0.18 $ 0.07 $ 0.37 $ 0.11

Adjusted diluted earnings per share (Non-GAAP) $ 0.30 $ 0.25 $ 0.57 $ 0.45

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited)

Explanations for Non-GAAP Reconciliations

(1)Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2026 primarily included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.

(2)For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.

(3)For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For the three and six months ended June 30, 2026, charges related to legal matters, including interest, net also included interest expense associated with the Nationwide Opioids Settlement Agreement. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

(4)For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.

(5)For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.

(6)Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information.

(7)Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.

(8)Gross leverage was calculated by dividing gross debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.

(9)Net leverage was calculated by dividing net debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.

(10)The non-GAAP effective tax rates for the three and six months ended June 30, 2026 were 25.1% and 24.7%, respectively. The non-GAAP effective tax rates for the three and six months ended June 30, 2025 were 24.7% and 25.0%, respectively.

(11)Weighted average diluted shares outstanding for the three and six months ended June 30, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities).

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 796,197 $ — $ 796,197 $ 724,508 $ — $ 724,508

Cost of goods sold (1)

461,689 (33,317) 428,372 438,255 (44,050) 394,205

Gross profit 334,508 33,317 367,825 286,253 44,050 330,303

Gross margin % 42.0 % 46.2 % 39.5 % 45.6 %

Selling, general and administrative (2)

148,722 (13,781) 134,941 124,266 (11,424) 112,842

Research and development (3)

39,017 (855) 38,162 47,964 (1,573) 46,391

Intellectual property legal development expenses 2,087 — 2,087 2,017 — 2,017

Acquisition costs (4)

7,600 (7,600) — — — —

Restructuring and other charges 554 — 554 1,024 (1,024) —

Charges (credits) related to legal matters, net (5)

8,057 (8,057) — (390) 390 —

Other operating income (1,298) — (1,298) — — —

Operating income $ 129,769 $ 63,610 $ 193,379 $ 111,372 $ 57,681 $ 169,053

(1) Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million in each period) and amortization expense ($32.3 million and $43.1 million).

(2) Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($8.6 million and $6.4 million), amortization expense ($2.6 million and $2.7 million), site closure costs ($0.5 million in each period), and other ($2.1 million and $1.8 million).

(3) Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.9 million in each period) and site closure costs (none and $0.7 million).

(4) Acquisition costs for the three months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.

(5) For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 1,518,716 $ — $ 1,518,716 $ 1,419,928 $ — $ 1,419,928

Cost of goods sold (1)

864,095 (61,628) 802,467 877,784 (87,565) 790,219

Gross profit 654,621 61,628 716,249 542,144 87,565 629,709

Gross margin % 43.1 % 47.2 % 38.2 % 44.3 %

Selling, general and administrative (2)

287,582 (25,062) 262,520 242,554 (20,971) 221,583

Research and development (3)

77,400 (1,628) 75,772 88,004 (3,053) 84,951

Intellectual property legal development expenses 3,629 — 3,629 3,784 — 3,784

Acquisition costs (4)

12,753 (12,753) — — — —

Restructuring and other charges 1,204 (499) 705 1,595 (1,595) —

Charges (credits) related to legal matters, net (5)

8,751 (8,751) — (390) 390 —

Other operating income (8,239) — (8,239) (5,122) — (5,122)

Operating income $ 271,541 $ 110,321 $ 381,862 $ 211,719 $ 112,794 $ 324,513

(1) Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.9 million), amortization expense ($59.6 million and $85.6 million), and asset impairment charges (none and $0.1 million).

(2) Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($15.6 million and $11.9 million), amortization expense ($5.3 million and $5.4 million), site closure costs ($1.0 million in each period), and other ($3.2 million and $2.6 million).

(3) Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.6 million and $1.7 million) and site closure costs (none and $1.4 million).

(4) Acquisition costs for the six months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.

(5) For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc.

Affordable Medicines Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported

Adjustments

Non-GAAP

Net revenue $ 489,913 $ — $ 489,913 $ 433,425 $ — $ 433,425

Cost of goods sold (2)

282,684 (14,513) 268,171 252,646 (11,171) 241,475

Gross profit 207,229 14,513 221,742 180,779 11,171 191,950

Gross margin % 42.3 % 45.3 % 41.7 % 44.3 %

Selling, general and administrative (3)

42,367 (2,939) 39,428 34,226 (2,183) 32,043

Research and development (4)

33,023 (725) 32,298 41,899 (777) 41,122

Intellectual property legal development expenses 2,002 — 2,002 1,978 — 1,978

Restructuring and other charges — — — 683 (683) —

Charges (credits) related to legal matters, net (5)

8,057 (8,057) — (390) 390 —

Other operating income (1,298) — (1,298) — — —

Operating income $ 123,078 $ 26,234 $ 149,312 $ 102,383 $ 14,424 $ 116,807

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million and $0.9 million) and amortization expense ($13.5 million and $10.3 million).

(3)Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.5 million and $1.6 million) and site closure costs ($0.5 million and $0.6 million).

(4)Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(5)For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc.

Affordable Medicines Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported

Adjustments

Non-GAAP

Net revenue $ 913,150 $ — $ 913,150 $ 848,133 $ — $ 848,133

Cost of goods sold (2)

515,128 (24,083) 491,045 495,279 (22,046) 473,233

Gross profit 398,022 24,083 422,105 352,854 22,046 374,900

Gross margin % 43.6 % 46.2 % 41.6 % 44.2 %

Selling, general and administrative (3)

83,685 (5,371) 78,314 67,941 (3,999) 63,942

Research and development (4)

66,309 (1,402) 64,907 72,879 (1,466) 71,413

Intellectual property legal development expenses 3,495 — 3,495 3,691 — 3,691

Restructuring and other charges — — — 683 (683) —

Charges (credits) related to legal matters, net (5)

8,751 (8,751) — (390) 390 —

Other operating income (8,239) — (8,239) (5,122) — (5,122)

Operating income $ 244,021 $ 39,607 $ 283,628 $ 213,172 $ 27,804 $ 240,976

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.8 million), amortization expense ($22.1 million and $20.1 million), and asset impairment charges (none and $0.1 million).

(3)Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($4.4 million and $2.9 million) and site closure costs ($1.0 million and $1.1 million).

(4)Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(5)For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc.

Specialty Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(unaudited; $ in thousands)

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 149,295 $ — $ 149,295 $ 128,043 $ — $ 128,043

Cost of goods sold (1)

48,265 (18,804) 29,461 55,795 (32,880) 22,915

Gross profit 101,030 18,804 119,834 72,248 32,880 105,128

Gross margin % 67.7 % 80.3 % 56.4 % 82.1 %

Selling, general and administrative (2)

40,095 (664) 39,431 30,314 (486) 29,828

Research and development (3)

5,994 (130) 5,864 6,065 (796) 5,269

Intellectual property legal development expenses 85 — 85 39 — 39

Restructuring and other charges — — — 341 (341) —

Operating income $ 54,856 $ 19,598 $ 74,454 $ 35,489 $ 34,503 $ 69,992

(1)Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.

(2)Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3)Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $0.7 million).

Amneal Pharmaceuticals, Inc.

Specialty Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(unaudited; $ in thousands)

Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 282,560 $ — $ 282,560 $ 236,340 $ — $ 236,340

Cost of goods sold (1)

91,285 (37,545) 53,740 108,878 (65,520) 43,358

Gross profit 191,275 37,545 228,820 127,462 65,520 192,982

Gross margin % 67.7 % 81.0 % 53.9 % 81.7 %

Selling, general and administrative (2)

74,786 (1,190) 73,596 61,292 (831) 60,461

Research and development (3)

11,091 (225) 10,866 15,125 (1,587) 13,538

Intellectual property legal development expenses 134 — 134 93 — 93

Restructuring and other charges 347 (347) — 471 (471) —

Operating income $ 104,917 $ 39,307 $ 144,224 $ 50,481 $ 68,409 $ 118,890

(1)Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.

(2)Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3)Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.2 million in each period) and site closure costs (none and $1.4 million).

Amneal Pharmaceuticals, Inc.

AvKARE Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 156,989 $ — $ 156,989 $ 163,040 $ — $ 163,040

Cost of goods sold 130,740 — 130,740 129,814 — 129,814

Gross profit 26,249 — 26,249 33,226 — 33,226

Gross margin % 16.7 % 16.7 % 20.4 % 20.4 %

Selling, general and administrative (2)

16,913 (2,648) 14,265 15,079 (2,700) 12,379

Operating income $ 9,336 $ 2,648 $ 11,984 $ 18,147 $ 2,700 $ 20,847

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.

Amneal Pharmaceuticals, Inc.

AvKARE Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 323,006 $ — $ 323,006 $ 335,455 $ — $ 335,455

Cost of goods sold 257,682 — 257,682 273,627 — 273,627

Gross profit 65,324 — 65,324 61,828 — 61,828

Gross margin % 20.2 % 20.2 % 18.4 % 18.4 %

Selling, general and administrative (2)

33,593 (5,296) 28,297 30,773 (5,400) 25,373

Operating income $ 31,731 $ 5,296 $ 37,027 $ 31,055 $ 5,400 $ 36,455

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.

GRAPHIC

Filename: image.jpg · Sequence: 6

Binary file (3187 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information Document

Jul. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 30, 2026

Entity Registrant Name

AMNEAL PHARMACEUTICALS, INC.

Entity Central Index Key

0001723128

Entity Emerging Growth Company

false

Entity File Number

001-38485

Entity Incorporation, State or Country Code

Entity Tax Identification Number

93-4225266

Entity Address, Address Line One

400 Crossing Blvd

Entity Address, City or Town

Bridgewater

Entity Address, State or Province

Entity Address, Postal Zip Code

08807

City Area Code

908

Local Phone Number

947-3120

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Common Stock, par value $0.01 per share

Trading Symbol

AMRX

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration